Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
NCT04623541
Recruiting
The study is a global, multi-center safety and efficacy trial of epcoritamab, an antibody also known as EPKINLY™ and GEN3013 (DuoBody®-CD3xCD20). Epcoritamab will be tested either in Relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) as: * Monotherapy, or * Combination therapy: * epcoritamab + venetoclax * epcoritamab + pirtobrutinib In Non-United States (US) Participants Only: Treatment-naïve (TN) high risk (HR) (CLL): • epcoritamab + pirtobrutinib Combination therapy for Ri... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: O'Neal Comprehensive Cancer Center at University of Alabama at Birmingham, Birmingham, Alabama +86 locations
Conditions: Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Treatment-naïve High Risk Chronic Lymphocytic Leukemia, Richter's Syndrome
Register for Updates
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
NCT06100744
Recruiting
Psoriatic arthritis (PsA) is a type of arthritis that happens when the body's immune system attacks healthy cells and tissues causing joint pain, stiffness, and swelling. Symptoms can get worse and go away for periods of time. PsA that begins before a patient's 16th birthday is called juvenile PsA (jPsA).This study will evaluate how safe risankizumab is for the treatment of psoriatic arthritis and to assess change in disease symptoms. Risankizumab is being studied for the treatment of jPsA and... Read More
Gender:
ALL
Ages:
Between 5 years and 18 years
Trial Updated:
07/30/2025
Locations: Arkansas Children's Hospital /ID# 258776, Little Rock, Arkansas +27 locations
Conditions: Juvenile Psoriatic Arthritis
Register for Updates
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
NCT06651281
Recruiting
Researchers want to learn more about tulisokibart (also known as MK-7240) in an extension study. Tulisokibart is a medicine designed to treat active, moderate to severe Crohn's disease (CD) and ulcerative colitis (UC). An extension study is a type of study where people who received tulisokibart in certain other studies for CD or UC (called a parent study) may be able to join this study. The goals of this study are to learn about the safety of tulisokibart over time in people with CD or UC, and i... Read More
Gender:
ALL
Ages:
All
Trial Updated:
07/30/2025
Locations: Connecticut Clinical Research Institute ( Site 0297), Bristol, Connecticut +37 locations
Conditions: Crohn Disease, Colitis, Ulcerative
Register for Updates
Prospective Clinical Assessment Study in Children With Hypochondroplasia
NCT06410976
Recruiting
This is a long-term, multicenter, non-interventional study of children ages 2.5 to \<17 years with hypochondroplasia (HCH).
Gender:
ALL
Ages:
Between 30 months and 16 years
Trial Updated:
07/30/2025
Locations: UCSF Benioff Children's Hospital, Oakland, California +24 locations
Conditions: Hypochondroplasia
Register for Updates
UK ENcorafenib and BInimetinib Real-world Study in Melanoma
NCT07022457
Recruiting
This is a prospective longitudinal multi-centre observational study conducted in the United Kingdom, in patients with metastatic cutaneous BRAF V600 mutation-positive melanoma assigned to receive encorafenib and binimetinib. The aim of this study is to learn about how encorafenib and binimetinib perform, patients' experiences of using them, and how they might affect patient's quality of life, in the real world, when these treatments are prescribed by doctors instead of in a clinical trial. Parti... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: Southend University Hospital, Westcliff-on-Sea, Essex +6 locations
Conditions: Metastatic Melanoma, BRAF V600 Mutation Positive
Register for Updates
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
NCT06671496
Recruiting
Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO). The main aim of the study is to know how well zasocitinib (TAK-279) works in participants with active PsA based on their previous experience with specific treatments. The participants will be treated with either zasocitinib, or placebo. Participants will be in the study for up to 60 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: Arizona Arthritis & Rheumatology Research, PLLC | Phoenix, AZ, Mesa, Arizona +122 locations
Conditions: Psoriatic Arthritis
Register for Updates
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001
NCT01760005
Recruiting
The purpose of this study is to assess the safety, tolerability, biomarker, cognitive and clinical efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with the study drug slows the rate of progression of cognitive/clinical impairment or improves disease-related biomarkers.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/30/2025
Locations: University of Alabama in Birmingham, Birmingham, Alabama +37 locations
Conditions: Alzheimers Disease, Dementia, Alzheimers Disease, Familial
Register for Updates
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
NCT05552157
Recruiting
The purpose is to evaluate the biomarker effect, safety, and tolerability of investigational study drugs in participants who are known to have an Alzheimer's disease (AD)-causing mutation. Stage 1 will determine if treatment with the study drug prevents or slows the rate of amyloid beta (Aβ) pathological disease accumulation demonstrated by Aβ positron emission tomography (PET) imaging. Stage 2 will evaluate the effect of early Aβ plaque reduction/prevention on disease progression by assessing d... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: University of Alabama in Birmingham, Birmingham, Alabama +34 locations
Conditions: Alzheimers Disease, Dementia, Alzheimers Disease, Familial
Register for Updates
DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease
NCT06384573
Recruiting
This is an open label study to treat dominantly inherited Alzheimer's disease (DIAD) mutation carrier participants from the DIAN-TU-001 gantenerumab Open Label Extension (OLE) period with lecanemab to determine the effects of amyloid removal on age of onset and clinical progression compared to external controls, if amyloid plaque as measured by amyloid PET can be fully removed in DIAD, and the effects of amyloid removal on biomarkers of disease progression.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: University of Alabama in Birmingham, Birmingham, Alabama +5 locations
Conditions: Alzheimer's Disease, Dementia, Alzheimer's Disease, Familial
Register for Updates
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
NCT06647498
Recruiting
The purpose of this research study is to test the study drug, referred to as remternetug, to determine its effectiveness for the study treatment of asymptomatic (at risk) Alzheimer disease in individuals with AD-causing mutations. This study will also investigate the effects of remternetug on biomarkers (measures of the disease including brain scans, blood and spinal fluid tests), examine safety data to identify any potential benefits or risks, and examine how well participants can tolerate remt... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: University of Alabama in Birmingham, Birmingham, Alabama +34 locations
Conditions: Alzheimers Disease, Dementia, Alzheimers Disease, Familial
Register for Updates
A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)
NCT05471856
Recruiting
This study is open to adults with different types of advanced cancer. People can take part if previous treatment was not successful, or no treatment exists. The purpose of this study is to find the highest dose of a medicine called BI 1703880 that people with advanced cancer can tolerate when taken together with ezabenlimab. BI 1703880 and ezabenlimab are medicines that may help the immune system fight cancer. In this study, BI 1703880 is given to people for the first time. Participants get B... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: Valkyrie Clinical Trials, Los Angeles, California +12 locations
Conditions: Solid Tumors
Register for Updates
Phase 4 Paediatric Study to Evaluate Sonazoid Safety and Efficacy for Contrast-Enhanced Ultrasound Liver Imaging
NCT06639828
Recruiting
Liver tumours, 40% of which are benign, account for 1% to 4% of all solid tumours in children. The benign tumours are mainly haemangiomas, liver hamartomas, and liver cell adenomas. The malignant tumours are mainly hepatoblastoma, hepatocellular carcinoma (HCC), malignant liver mesothelioma, and rhabdomyosarcoma. The differential diagnosis of liver masses in children is generally based on the child's age, the clinical evaluation (including alpha-fetoprotein test results), and imaging characteris... Read More
Gender:
ALL
Ages:
18 years and below
Trial Updated:
07/30/2025
Locations: Munich University Hospital, München, Not set +5 locations
Conditions: Focal Liver Lesions
Register for Updates